Pacira Biosciences Chief Medical Officer sells $16,173 worth of stock By Investing.com

Jonathan Slonin, head Medical (TASE:) Officer at Pacira BioSciences, Inc. (NASDAQ: PCRX ), a healthcare company with a market capitalization of $858 million and a “GREAT” InvestingPro Financial Health Point, recently sold 879 shares of the company’s common stock. The transaction, executed on January 6, 2025, was completed at a price of $18.40 per share, for a total of $16,173. This sale was conducted under a Rule 10b5-1 business plan that Slonin had previously adopted. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment, with 5 analysts recently revising their earnings expectations upwards.

In addition, on January 2, 2025, Slonin disposed of 371 shares at $18.33 each to cover tax obligations related to the award of restricted stock units. After these transactions, Slonin holds 93,443,511 shares of Pacira BioSciences, which includes shares acquired through the company’s employee stock purchase plan in December 2024. For a more in-depth view of the insider’s trading patterns and a complete analysis, including 8 additional ProTips, check out the Pro Research report. available on InvestingPro.

In other recent news, Pacira BioSciences, Inc. reported significant developments in its non-opioid pain management solutions. The company’s gene therapy candidate, PCRX-201, showed sustained improvements in knee pain, stiffness and function for up to 104 weeks in patients with moderate to severe osteoarthritis in a phase I trial 1. This progress is expected to be presented at the annual meeting of the American College of Rheumatology.

On the financial front, Pacira’s third quarter 2024 results showed an increase in EXPAREL sales from $128.7 million to $132 million. The company’s non-GAAP gross margin was 78%, and adjusted EBITDA was reported at $54.7 million. Despite the challenges with ZILRETTA, the company maintained its 2024 revenue guidance of $680 million to $705 million, with adjusted gross margins between 74% and 76%.

In the earnings call, Pacira emphasized its strategic focus on patient care and non-opioid pain therapies, in view of accelerated growth in 2025. The company also highlighted the upcoming implementation of the policy of reimbursement NOPAIN, which is expected to improve access to EXPAREL. early January 2025. These recent developments reinforce Pacira’s continued commitment to providing innovative pain management solutions.

This article was generated with AI support and reviewed by an editor. For more information see our T&C.